1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,077 | 0,174 | 03.10. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| CANTARGIA Aktie jetzt für 0€ handeln | |||||
| Mi | Cantargia Highlights Preclinical Data at AACR Supporting Nadunolimab in Combination with RAS Inhibition in PDAC | 298 | ACCESS Newswire | LUND, SE / ACCESS Newswire / September 30, 2026 / Cantargia AB (publ) (STO:CANTA) today announced the presentation of a poster on nadunolimab in combination with RAS inhibition in pancreatic ductal... ► Artikel lesen | |
| 14.09. | Cantargia auf der H.C. Wainwright Konferenz: IL1RAP-Daten im Fokus | 5 | Investing.com Deutsch | ||
| 28.08. | Cantargia to Participate in Upcoming Investor Conferences | 450 | ACCESS Newswire | LUND, SE / ACCESS Newswire / August 28, 2026 / Cantargia AB (publ) (Nasdaq Stockholm:CANTA) today announced that management will participate in the following investor conferences during September 2026.H.C.... ► Artikel lesen | |
| 19.08. | Cantargia Q2 2026 slides: cash runway extends, MDS remissions shine | 1 | Investing.com | ||
| 19.08. | Cantargia Publishes Half-Year Report 2026 | 463 | ACCESS Newswire | LUND, SE / ACCESS Newswire / August 19, 2026 / Cantargia AB (publ) (STO:CANTA) today published its interim report for the second quarter and first six months of 2026."Over the next nine to twelve months... ► Artikel lesen | |
| 19.08. | Cantargia AB: Cantargia publishes Half-Year Report 2026 | 225 | GlobeNewswire (Europe) | Cantargia AB (publ) (Nasdaq Stockholm: CANTA) today published its interim report for the second quarter and first six months of 2026.
"Over the next nine to twelve months, we will lay the groundwork... ► Artikel lesen | |
| 04.08. | Cantargia to Host Q2 2026 Interim Results Conference Call | 333 | ACCESS Newswire | LUND, SE / ACCESS Newswire / August 4, 2026 / Cantargia AB (publ), "Cantargia" (STO:CANTA) will publish its interim report for January - June 2026 on Wednesday, August 19, 2026, at 07:00 a.m. CEST.Interested... ► Artikel lesen | |
| 31.07. | Cantargia Announces Changes in Number of Shares and Votes | 556 | ACCESS Newswire | LUND, SE / ACCESS Newswire / July 31, 2026 / Cantargia AB (publ) ("Cantargia") (Nasdaq Stockholm:CANTA) today announced that the number of shares and votes in Cantargia has changed due to the recently... ► Artikel lesen | |
| 26.06. | Cantargia Announces Publication of Data Supporting IL1RAP as a Therapeutic Target and Predictive Biomarker in PDAC | 425 | ACCESS Newswire | LUND, SE / ACCESS Newswire / June 26, 2026 / Cantargia AB (publ) (STO:CANTA) today announced the publication of preclinical and clinical findings from the nadunolimab trial CANFOUR in the scientific... ► Artikel lesen | |
| 23.06. | Cantargia AB: Cantargia announces outcome in rights issue and resolves on a directed issue of warrants to Fenja Capital | 271 | GlobeNewswire (Europe) | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SINGAPORE... ► Artikel lesen | |
| 11.06. | Cantargia and H.C. Wainwright to Host KOL Call on The Case for Nadunolimab in PDAC | 325 | ACCESS Newswire | LUND, SE / ACCESS Newswire / June 11, 2026 / Cantargia AB (Publ) (STO:CANTA) today announced a KOL Call to be hosted in collaboration with H.C. Wainwright with leading subject matter experts Drs. Peter... ► Artikel lesen | |
| 10.06. | Cantargia Announces Start of New Investigator-Initiated Lung Cancer Prevention Study | 421 | ACCESS Newswire | LUND, SE / ACCESS Newswire / June 10, 2026 / Cantargia AB (Publ) (STO:CANTA) today reported that the first patient has been dosed in a Phase 2 clinical trial investigating nadunolimab in up to 59 current... ► Artikel lesen | |
| 05.06. | Cantargia AB: Cantargia publishes Information Document regarding Rights Issue of Shares | 322 | GlobeNewswire (Europe) | Cantargia AB (publ) ("Cantargia" or the "Company") publishes an information document (the "Information Document") relating to the rights issue of shares of approximately SEK 124 million before deduction... ► Artikel lesen | |
| 03.06. | XFRA CAPITAL ADJUSTMENT INFORMATION - 03.06.2026 | 618 | Xetra Newsboard | Das Instrument 7V3 SE0006371126 CANTARGIA AB EQUITY wird ex Kapitalmassnahme gehandelt am 03.06.2026 The instrument 7V3 SE0006371126 CANTARGIA AB EQUITY is traded ex capital adjustment on 03.06.2026Das... ► Artikel lesen | |
| 28.05. | Cantargia AB to Host Webcast Covering Rights Issue, Loan Agreement, and Strategic Priorities | 447 | ACCESS Newswire | LUND, SE / ACCESS Newswire / May 28, 2026 / Cantargia (STO:CANTA) - With reference to the Company's press release on May 28, 2026, regarding the decision to conduct a rights issue in combination with... ► Artikel lesen | |
| 28.05. | Cantargia AB: Cantargia AB carries out a rights issue of SEK 124 million and enters into a loan agreement of up to SEK 75 million | 622 | GlobeNewswire (Europe) | Cantargia AB (publ) ("Cantargia" or the "Company") hereby announces that the board of directors has resolved to carry out a new share issue of approximately SEK 124 million with preferential rights... ► Artikel lesen | |
| 21.05. | Bulletin from the Annual General Meeting in Cantargia AB | 431 | ACCESS Newswire | LUND, SE / ACCESS Newswire / May 21, 2026 / Cantargia (STO:CANTA) - The Annual General Meeting of Cantargia AB (publ) on May 21, 2026 resolved in accordance with the following:To adopt the income statement... ► Artikel lesen | |
| 19.05. | Cantargia Publishes Interim Report for The First Quarter of 2026 | 496 | ACCESS Newswire | LUND, SE / ACCESS Newswire / May 19, 2026 / Cantargia AB (publ); Nasdaq Stockholm:CANTA) today announced its interim report for the first quarter of 2026."The first quarter of 2026 reflects both strong... ► Artikel lesen | |
| 06.05. | Invitation to the Presentation of Cantargia's Interim Report for Q1 2026 | 384 | ACCESS Newswire | LUND, SE / ACCESS Newswire / May 6, 2026 / Cantargia AB (publ) (Nasdaq Stockholm:CANTA) will publish the company's interim report for Q1 2026 on Tuesday, May 19, 2026, at 07:00 a.m. CEST.In conjunction... ► Artikel lesen | |
| 27.04. | Cantargia Announces Early Results from Trial of Nadunolimab in MDS and AML | 466 | ACCESS Newswire | LUND, SE / ACCESS Newswire / April 27, 2026 / Cantargia AB (Nasdaq Stockholm:CANTA), a clinical-stage biotechnology company focused on antibody-based therapeutics targeting IL1RAP, today announced early... ► Artikel lesen |
1 2 Weiter >>
34 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 86,00 | -0,12 % | Biontech-Standorte offenbar vor dem Aus | Idar-Oberstein/Tübingen/Marburg - Die Biontech-Standorte in Idar-Oberstein, Tübingen und Marburg stehen offenbar vor dem Aus. Wie der SWR und der HR am Montag berichten, habe sich für die Werke keine... ► Artikel lesen | |
| EVOTEC | 2,920 | -3,57 % | Evotec-Aktie: Wie lange noch im Abwärtsstrudel? | Die Evotec-Aktie startet mit leichten Gewinnen in die neue Woche und notiert aktuell bei rund 2,83 €. Von einer echten Entspannung kann dennoch keine Rede sein, denn der Titel bewegt sich weiterhin... ► Artikel lesen | |
| QIAGEN | 40,405 | +5,80 % | Qiagen-Aktie: Was die Spuren im Labor verraten - Warren Wise Podcast | Ein verlässliches Geschäft mit einer Zukunftsgeschichte, die Fragen aufwirft. Qiagen liefert den ersten Handgriff vieler molekularer Untersuchungen: Das Unternehmen löst Erbgut aus Blut, Gewebe oder... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 648,50 | -0,72 % | Sanofi und Regeneron erweitern Allianz in Milliardendeal | DJ Sanofi und Regeneron erweitern Allianz in Milliardendeal
Von Adria Calatayud
DOW JONES--Sanofi und Regeneron Pharmaceuticals weiten ihre Kooperation zur gemeinsamen Entwicklung und Vermarktung... ► Artikel lesen | |
| BRAIN BIOTECH | 2,830 | -2,75 % | Brain Biotech erhält 11,5 Millionen Euro - hoher Buchungseffekt belastet | Brain Biotech erhält von Royalty Pharma eine Meilensteinzahlung von 11,51 Millionen Euro. Auslöser ist ein Entwicklungsfortschritt beim Pharmawirkstoff Deucrictibant auf Basis der 2024 geschlossenen... ► Artikel lesen | |
| SCORPIUS | - | - | Scorpius Holdings, Inc. - 8-K, Current Report | ||
| CARDIOL THERAPEUTICS | 1,258 | 0,00 % | Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): Buy | Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH
02.10.2026 / 12:56 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The... ► Artikel lesen | |
| CSL | 107,06 | -0,59 % | CSL Seqirus Expands U.S. Influenza Vaccine Availability Ahead Of Flu Season | CANBERA (dpa-AFX) - Tuesday, CSL Seqirus, a business of CSL (CSL.AX), said it has expanded the availability of influenza vaccines in the U.S. following the successful completion of its 2026/27... ► Artikel lesen | |
| BURCON NUTRASCIENCE | 0,785 | 0,00 % | Burcon NutraScience Corporation: Burcon Announces Shareholder Meeting Results and Updates Commercial Guidance | Customer demand remains strong as Company accelerates investment in manufacturing infrastructure and reliabilityVancouver, British Columbia--(Newsfile Corp. - September 24, 2026) - Burcon NutraScience... ► Artikel lesen | |
| MANNKIND | 3,533 | +4,77 % | MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management | Collaboration combines Rose Pharma investigational rapid-acting GLP-1 receptor agonist with MannKind's Technosphere- inhalation technologyMannKind to receive an equity interest and potential royalties... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 6,200 | 0,00 % | RBC Capital bestätigt Rating für Ocular Therapeutix und sieht Potenzial in AMD-Therapie | ||
| OXFORD NANOPORE TECHNOLOGIES | 2,626 | +0,15 % | IP Group sells down stake in Oxford Nanopore | ||
| ADAPTIMMUNE THERAPEUTICS | 0,025 | 0,00 % | Merck And ADAP Crisis Task Force Reach Agreement To Expand IDVYNSO Access | ||
| CODEXIS | 1,232 | +1,57 % | Codexis, Inc.: Codexis Enters into an Agreement with Pioneering siRNA Drug Innovator to Leverage the ECO Synthesis Manufacturing Platform to Create Stereo-defined siRNA | REDWOOD CITY, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced... ► Artikel lesen | |
| CORMEDIX | 6,320 | 0,00 % | CorMedix, Inc.: Cormedix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update | - Q2 2026 Consolidated Revenue of $101.9 million - - Q2 2026 Net Income of $26.0 million; Adjusted EBITDA of $58.7 million - - Company Maintains FY 2026 Revenue and Raises Adjusted EBITDA Guidance... ► Artikel lesen |
Das Unternehmen CANTARGIA AB kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -4,44 % bei einem Aktienkurs von 0,095 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CANTARGIA AB finden Sie auf Wallstreet Online.